716 related articles for article (PubMed ID: 17062306)
1. Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series.
Huang YW; Liu CJ; Lai MY; Lee PH; Tsai MK; Wang SS; Lai MK; Kao JH
Clin Ther; 2006 Sep; 28(9):1327-34. PubMed ID: 17062306
[TBL] [Abstract][Full Text] [Related]
2. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients.
Chan TM; Fang GX; Tang CS; Cheng IK; Lai KN; Ho SK
Hepatology; 2002 Nov; 36(5):1246-52. PubMed ID: 12395336
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.
Castells L; Vargas V; Rodríguez F; Allende H; Buti M; Sánchez-Avila JF; Jardí R; Margarit C; Pumarola T; Esteban R; Guardia J
Liver Transpl; 2002 Oct; 8(10):892-900. PubMed ID: 12360430
[TBL] [Abstract][Full Text] [Related]
4. The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy.
Gwak GY; Huh W; Lee DH; Choi MS; Lee JH; Koh KC; Kim SJ; Joh JW; Oh HY
Transplant Proc; 2007 Dec; 39(10):3121-6. PubMed ID: 18089336
[TBL] [Abstract][Full Text] [Related]
5. Reactivation of hepatitis and lamivudine therapy in 11 HBsAg-positive renal allograft recipients: a single centre experience.
Murakami R; Amada N; Sato T; Orii T; Kikuchi H; Haga I; Ohashi Y; Okazaki H
Clin Transplant; 2006; 20(3):351-8. PubMed ID: 16824154
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of hepatitis B virus infection with Lamivudine after heart transplantation.
Wang SS; Chou NK; Chi NH; Hsu RB; Huang SC; Chen YS; Yu HY; Tsao CI; Ko WJ; Lai MY; Chu SH
Transplant Proc; 2006 Sep; 38(7):2138-40. PubMed ID: 16980024
[TBL] [Abstract][Full Text] [Related]
7. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.
Yalçin K; Değertekin H; Kokoğlu OF; Ayaz C
Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116
[TBL] [Abstract][Full Text] [Related]
8. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation.
Ben-Ari Z; Mor E; Shapira Z; Tur-Kaspa R
Liver Transpl; 2001 Feb; 7(2):113-7. PubMed ID: 11172394
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome of renal transplantation in patients with positive pre-transplant hepatitis B surface antigen.
Ahn HJ; Kim MS; Kim YS; Kim SI; Huh KH; Ju MK; Ahn SH; Han KH
J Med Virol; 2007 Nov; 79(11):1655-63. PubMed ID: 17854044
[TBL] [Abstract][Full Text] [Related]
10. Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation.
Shitrit AB; Kramer MR; Bakal I; Morali G; Ben Ari Z; Shitrit D
Ann Thorac Surg; 2006 May; 81(5):1851-2. PubMed ID: 16631684
[TBL] [Abstract][Full Text] [Related]
11. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
Viganò M; Colombo M; Aroldi A; Lunghi G; Manenti E; Ponticelli C; Lampertico P
Antivir Ther; 2005; 10(6):709-13. PubMed ID: 16218169
[TBL] [Abstract][Full Text] [Related]
12. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients.
Lee WC; Wu MJ; Cheng CH; Chen CH; Shu KH; Lian JD
Am J Kidney Dis; 2001 Nov; 38(5):1074-81. PubMed ID: 11684562
[TBL] [Abstract][Full Text] [Related]
13. Lamivudine therapy in kidney allograft recipients who are seropositive for hepatitis B surface antigen.
Filik L; Karakayali H; Moray G; Dalgiç A; Emiroğlu R; Ozdemir N; Colak T; Gür G; Yilmaz U; Haberal M
Transplant Proc; 2006 Mar; 38(2):496-8. PubMed ID: 16549158
[TBL] [Abstract][Full Text] [Related]
14. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts.
Vizzini G; Gruttadauria S; Volpes R; D'Antoni A; Pietrosi G; Filì D; Petridis I; Pagano D; Tuzzolino F; Santonocito MM; Gridelli B
Clin Transplant; 2011; 25(1):E77-81. PubMed ID: 21039887
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
Chan HL; Chui AK; Lau WY; Chan FK; Wong ML; Tse CH; Rao AR; Wong J; Sung JJ
J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406
[TBL] [Abstract][Full Text] [Related]
16. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B.
Lo CM; Liu CL; Chan SC; Lau GK; Fan ST
J Hepatol; 2005 Aug; 43(2):283-7. PubMed ID: 15964658
[TBL] [Abstract][Full Text] [Related]
17. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
Huang H; Cai Q; Lin T; Lin X; Liu Y; Gao Y; Peng R
Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
[TBL] [Abstract][Full Text] [Related]
18. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
[TBL] [Abstract][Full Text] [Related]
20. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients.
Hsiao LT; Chiou TJ; Liu JH; Chu CJ; Lin YC; Chao TC; Wang WS; Yen CC; Yang MH; Tzeng CH; Chen PM
Biol Blood Marrow Transplant; 2006 Jan; 12(1):84-94. PubMed ID: 16399572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]